Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 89
Filtrar
1.
Nutrients ; 13(3)2021 Feb 26.
Artigo em Inglês | MEDLINE | ID: mdl-33652862

RESUMO

Bariatric surgery is an effective intervention for management of obesity through treating dysregulated appetite and achieving long-term weight loss maintenance. Moreover, significant changes in glucose homeostasis are observed after bariatric surgery including, in some cases, type 2 diabetes remission from the early postoperative period and postprandial hypoglycaemia. Levels of a number of gut hormones are dramatically increased from the early period after Roux-en-Y gastric bypass and sleeve gastrectomy-the two most commonly performed bariatric procedures-and they have been suggested as important mediators of the observed changes in eating behaviour and glucose homeostasis postoperatively. In this review, we summarise the current evidence from human studies on the alterations of gut hormones after bariatric surgery and their impact on clinical outcomes postoperatively. Studies which assess the role of gut hormones after bariatric surgery on food intake, hunger, satiety and glucose homeostasis through octreotide use (a non-specific inhibitor of gut hormone secretion) as well as with exendin 9-39 (a specific glucagon-like peptide-1 receptor antagonist) are reviewed. The potential use of gut hormones as biomarkers of successful outcomes of bariatric surgery is also evaluated.


Assuntos
Cirurgia Bariátrica , Glicemia/efeitos dos fármacos , Hormônios Gastrointestinais/farmacologia , Obesidade Mórbida/terapia , Redução de Peso/efeitos dos fármacos , Adulto , Biomarcadores/sangue , Terapia Combinada , Ingestão de Alimentos/efeitos dos fármacos , Feminino , Gastrectomia , Derivação Gástrica , Hormônios Gastrointestinais/sangue , Humanos , Fome/efeitos dos fármacos , Masculino , Pessoa de Meia-Idade , Obesidade Mórbida/sangue , Octreotida/sangue , Octreotida/farmacologia , Fragmentos de Peptídeos/sangue , Fragmentos de Peptídeos/farmacologia , Período Pós-Operatório , Saciação/efeitos dos fármacos , Resultado do Tratamento
2.
Talanta ; 217: 121025, 2020 Sep 01.
Artigo em Inglês | MEDLINE | ID: mdl-32498910

RESUMO

Agarose gel as a green membrane has been proposed for use in electromembrane extraction of five hypothalamic-related peptides without an ionic carrier. Octreotide, goserelin, triptorelin, cetrorelix, and somatostatin were extracted from 5.0 mL of sample solution (adjusted to pH 5.0) into a microvolume acceptor solution (HCl, 100 mM) under the applied voltage of 30 V in 15 min. The pH of the agarose gel 3.0% (w/v) was adjusted to 4.0 to facilitate the movement of peptides through the membrane. Quantification was performed using an HPLC-UV system on a C18 column. Quantification and detection limits were found to be in the range of 15.0-20.0 ng mL-1 and 4.5-6.0 ng mL-1, respectively. Dynamic linear ranges were found to be in the range of 15.0-1000 ng mL-1 (R2 > 0.995) and recoveries were in the range of 62.3-77.6%. The optimized method was applied to spiked human plasma samples. The method showed relative recoveries in the range of 44.8-66.0%. Finally, the proposed method was compared with and shown to have higher recoveries than, the conventional electromembrane extraction method for the peptides under study.


Assuntos
Hormônio Liberador de Gonadotropina/análogos & derivados , Gosserrelina/sangue , Octreotida/sangue , Peptídeos/química , Somatostatina/sangue , Pamoato de Triptorrelina/sangue , Técnicas Eletroquímicas , Géis/química , Hormônio Liberador de Gonadotropina/sangue , Hormônio Liberador de Gonadotropina/química , Gosserrelina/química , Voluntários Saudáveis , Humanos , Octreotida/química , Somatostatina/química , Pamoato de Triptorrelina/química
3.
Anal Chim Acta ; 1114: 42-49, 2020 Jun 01.
Artigo em Inglês | MEDLINE | ID: mdl-32359513

RESUMO

Disulfide-cyclized peptides, including the somatostatin receptor agonist octreotide, are usually resistant against collision-induced dissociation (CID) complicating their bioanalysis by MS/MS. Post-extraction reductive cleavage of the disulfide bridge of such peptides utilizing tris(2-carboxyethyl)phosphine generates the corresponding linear dithiol-peptides. This procedure enables monitoring of larger, specific fragments in CID which usually avoid matrix interference present for single amino acid iminium ions abundant in CID of the intact peptides. To assist formulation development for oral administration of the cystine-cyclized therapeutic peptide octreotide, we applied this methodology to the development of an ultra-sensitive UPLC-MS/MS assay for plasma octreotide and validated it according to FDA's and EMA's pertinent guidelines. Octreotide was extracted from plasma by fast and simple protein precipitation with acetonitrile and subsequently reduced to linear dithiol-octreotide for the monitoring of specific fragments in selected reaction monitoring. The calibrated concentration range of 10 (9.8 pM) to 20,000 pg mL-1 was linear with correlation coefficients > 0.99. Interday accuracy ranged between 100.0 and 108.9% with corresponding precision of <8.1%. The assay was successfully applied to the quantification of octreotide plasma concentrations after intravenous administration in beagle dogs. The presented procedure of disrupting the cyclic structure of cystine-cyclized peptides by reductive cleavage of the intramolecular disulfide bond enables the generation of more specific and intense fragments in CID can serve as a general methodology for the sensitive bioanalysis of cystine-bearing cyclic peptides.


Assuntos
Cistina/análise , Dissulfetos/química , Octreotida/sangue , Peptídeos Cíclicos/análise , Animais , Cromatografia Líquida de Alta Pressão , Cães , Espectrometria de Massas em Tandem
4.
J Nucl Med ; 61(9): 1337-1340, 2020 09.
Artigo em Inglês | MEDLINE | ID: mdl-32005767

RESUMO

Peptide receptor radiotherapy using 177Lu-labeled somatostatin ligand analogs is a well-established treatment for neuroendocrine tumors, with 177Lu-DOTATATE having acquired marketing authorization in Europe and the United States. The investigation of the pharmacokinetics of these radiopharmaceuticals in vivo in humans is crucial for personalized treatment management and understanding of treatment effects. Such an investigation requires input data on the in vivo stability of the radiopharmaceuticals in blood and plasma. The work presented here is devoted to the investigation of the in vivo stability of 177Lu-DOTATATE in humans affected by neuroendocrine tumors. Methods: Blood samples of 6 patients undergoing 177Lu-DOTATATE were taken at 0.5, 4, 24, and 96 h after injection. Analysis of metabolic stability was performed using high-performance liquid chromatography. Results: A fast metabolism of the radiopharmaceutical was observed, with the fraction of intact 177Lu-DOTATATE in plasma decreasing rapidly to 23% ± 5% (mean ± SD) at 24 h and 1.7% ±0. 9% at 96 h after injection. Conclusion: The in vivo stability of 177Lu-DOTATATE is much lower than previously assumed, with the major part of radioactivity in plasma consisting of 177Lu-labeled metabolites already at 24 h after injection.


Assuntos
Tumores Neuroendócrinos/metabolismo , Tumores Neuroendócrinos/radioterapia , Octreotida/análogos & derivados , Compostos Organometálicos/metabolismo , Compostos Organometálicos/uso terapêutico , Receptores de Peptídeos/metabolismo , Estabilidade de Medicamentos , Humanos , Tumores Neuroendócrinos/sangue , Octreotida/sangue , Octreotida/metabolismo , Octreotida/uso terapêutico , Compostos Organometálicos/sangue
5.
Mater Sci Eng C Mater Biol Appl ; 102: 820-828, 2019 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-31147054

RESUMO

Poly(d,l-lactide-co-glycolide) (PLGA) microspheres have been used as an injectable depot for prolonged release of octreotide (Sandostatin LAR®), a peptide drug for the treatment of acromegaly and gastrointestinal tumors. However, acylation and incomplete release of the encapsulated octreotide, as well as acidic degradation product-induced inflammation are the major challenges hampering widespread clinical applications of this delivery system. The purpose of this study was to develop a novel octreotide-delivering system utilizing naturally derived biodegradable material, silk fibroin (SF). Octreotide acetate was encapsulated in the SF microspheres with a high loading (8-10 wt%) using polyethylene glycol (PEG)-assisted emulsification method. The octreotide-SF microspheres exhibited a silk I structure (low crystallinity) and burst release in in vitro release studies. Ethanol treatment after microsphere formation significantly increased ß-sheet and silk II structure (high crystallinity) of the microspheres, significantly reducing the burst release and resulting in zero-order sustained release of octreotide over 102 days, and the data could be fit to the diffusion-driven release model. After the ethanol-treated microspheres were intramuscularly injected into rats at low (2 mg/kg) and high (8 mg/kg) octreotide doses, the plasma concentration of octreotide in the high dose group remained high (>50 pg/mL) at day 28 when compared to that of the control (pure drug at low dose) and low dose microsphere group. Interestingly, the plasma concentration for the high dose group at day 56 dramatically increased to >280 pg/mL observed at day 28. The low dose microsphere group showed a similar increase, but at a much lower level. The rebound octreotide level likely reflected degradation of the SF matrix which released tightly bound/trapped octreotide. Therefore, SF microspheres can deliver octreotide over a long period of time with release kinetics and the mechanism different from PLGA microsphere system.


Assuntos
Liberação Controlada de Fármacos , Fibroínas/química , Microesferas , Octreotida/farmacocinética , Animais , Bombyx , Etanol/química , Feminino , Metanol/química , Octreotida/sangue , Tamanho da Partícula , Ratos Sprague-Dawley
6.
Clin Pharmacokinet ; 58(2): 213-222, 2019 02.
Artigo em Inglês | MEDLINE | ID: mdl-29736841

RESUMO

BACKGROUND AND OBJECTIVE: 177Lu-Dotatate is a radio-labeled analog of somatostatin used in the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors. In order to prevent nephrotoxic effects of 177Lu-Dotatate a co-infusion of amino acids (AA) is administered, resulting in a decrease in tubular renal reabsorption of 177Lu-Dotatate. This study aimed to quantify the impact of AA co-infusion on the pharmacokinetics of 177Lu-Dotatate in cancer patients and to evaluate its relationship with toxicity during the first treatment cycle (C1). METHODS: 7.4 GBq of 177Lu-Dotatate was administered to 42 patients over a 30-min intravenous infusion. Infusion of AA started 2 h before and continued for 6 h after the infusion of 177Lu-Dotatate. Radioactivity-time data (n = 346) were analyzed using NONMEM® (version 7.2.0). RESULTS: 177Lu-Dotatate pharmacokinetics was best described by a three-compartment model with first-order elimination. AA co-infusion had a significant effect ('fixed effect') on 177Lu-Dotatate pharmacokinetics, with a mean value of 1.5-fold (95% confidence interval 1.03-1.97) increase in the elimination rate constant (k10) from 0.204 to 0.306 h-1, but this AA co-infusion effect was associated with a large inter-individual variability (IIV) of 104%. The individual k10 values increased during concomitant AA infusion by a factor ranging from 1.01 to 21.3 for 27 patients, whereas the opposite effect was observed in 15 patients (range 0.36-0.99) of whom seven had a k10 value lower than 0.85. This variability in AA effect contributed to the variability in 177Lu-Dotatate plasma exposure (area under the concentration-time curve from time zero to Day 15 for C1 [AUCDay15]) that correlated with lymphopenia observed at Day 15 (p = 0.004). CONCLUSIONS: A substantial effect of AA co-infusion on 177Lu-Dotatate pharmacokinetics was shown but was associated with high IIV, contributing to IIV in hematological toxicity.


Assuntos
Aminoácidos/administração & dosagem , Antineoplásicos/farmacocinética , Neoplasias Intestinais/metabolismo , Modelos Biológicos , Tumores Neuroendócrinos/metabolismo , Octreotida/análogos & derivados , Compostos Organometálicos/farmacocinética , Neoplasias Pancreáticas/metabolismo , Neoplasias Gástricas/metabolismo , Adulto , Idoso , Idoso de 80 Anos ou mais , Antineoplásicos/efeitos adversos , Antineoplásicos/sangue , Feminino , Humanos , Infusões Intravenosas , Rim/efeitos dos fármacos , Contagem de Linfócitos , Masculino , Pessoa de Meia-Idade , Octreotida/efeitos adversos , Octreotida/sangue , Octreotida/farmacocinética , Compostos Organometálicos/efeitos adversos , Compostos Organometálicos/sangue
7.
Radiat Environ Biophys ; 57(1): 55-61, 2018 03.
Artigo em Inglês | MEDLINE | ID: mdl-29149420

RESUMO

The main target of this work is to examine blood clearance and external exposure for 177Lu-DOTATATE compared with new emerging 177Lu-PSMA therapy. Blood clearance and radiation exposure of 31 patients treated with 5.5 ± 1.1 GBq 177Lu-DOTATATE were compared to those of 23 patients treated with 7.4 GBq 177Lu-PSMA. Dose rates were measured at several distances and time points up to 120 h after treatment. Blood samples were collected conjunctively after infusion. Caregiver's cumulative dose was measured by means of an OSL (optically stimulated luminescence) dosimeter for 4-5 days and medical staff's dose was also estimated using electronic personal dosimeters. Finger dose was determined via ring TLD (Thermoluminescence Dosimeter) for radiopharmacists and nurses. Dose rates due to 177Lu-DOTATATE at a distance of 1 m, 4 h and 6 h after infusion, were 3.0 ± 2.8 and 2 ± 1.9 µSv/(h GBq), respectively, while those due to 177Lu-PSMA were 3.1 ± 0.8 and 2.2 ± 0.9 µSv/(h GBq). Total effective dose of 17 caregivers was 100-200 µSv for 177Lu-DOTATATE therapy. Mean effective doses to nurses and radiopharmacists were 5 and 4 µSv per patient, respectively, while those for physicists and physicians were 2 µSv per patient. For 177Lu-DOTATATE, effective half-life in blood and early elimination phase were 0.31 ± 0.13 and 4.5 ± 1 h, while they were found as 0.4 ± 0.1 and 5 ± 1 h, respectively, for 177Lu-PSMA. The first micturition time following 177Lu-DOTATATE infusion was noted after 36 ± 14 min, while the second and third voiding times were after 74 ± 9 and 128 ± 41 min, respectively. It is concluded that blood clearance and radiation exposure for 177Lu-DOTATATE are very similar to those for 177Lu-PSMA, and both treatment modalities are reasonably reliable for outpatient treatment, since the mean dose rate [2.1 µSv/(h GBq)] decreased below the dose rate that allows release of the patient from the hospital (20 µSv/h) after 6 h at 1 m distance.


Assuntos
Dipeptídeos/sangue , Dipeptídeos/farmacocinética , Compostos Heterocíclicos com 1 Anel/sangue , Compostos Heterocíclicos com 1 Anel/farmacocinética , Octreotida/análogos & derivados , Compostos Organometálicos/sangue , Compostos Organometálicos/farmacocinética , Dipeptídeos/uso terapêutico , Pessoal de Saúde , Compostos Heterocíclicos com 1 Anel/uso terapêutico , Humanos , Lutécio , Exposição Ocupacional , Octreotida/sangue , Octreotida/farmacocinética , Octreotida/uso terapêutico , Compostos Organometálicos/uso terapêutico , Antígeno Prostático Específico , Distribuição Tecidual
8.
Clin Pharmacol Ther ; 101(4): 462-468, 2017 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-28032910

RESUMO

In the RADIANT-2 trial, addition of everolimus to octreotide long-acting repeatable (LAR) exhibited a clinically meaningful 5.1-month improvement in progression-free survival (PFS) in patients with advanced functional neuroendocrine tumors. In this study, we characterized the effects of everolimus co-administration on octreotide LAR pharmacokinetics and its relationship with efficacy and safety. At least one evaluable blood everolimus and plasma octreotide predose minimum concentration (Cmin ) was available for 182 patients and 294 patients, respectively. Concomitant everolimus administration increased octreotide Cmin with a geometric mean ratio (everolimus/placebo) of 1.47 (90% confidence interval [CI] = 1.32-1.64). Risk for progression was consistently reduced when everolimus Cmin was increased twofold, regardless of octreotide exposure (hazard ratio [HR] = 0.74; 95% CI = 0.46-1.18; HR = 0.54; 95% CI = 0.32-0.92 for 6 ng/mL and 4 ng/mL octreotide, respectively). Risk for pulmonary or metabolic events was associated with increased everolimus Cmin . Co-administration of everolimus plus octreotide LAR increased octreotide Cmin , which did not impact efficacy.


Assuntos
Antineoplásicos/farmacologia , Ensaios Clínicos Fase III como Assunto/métodos , Everolimo/farmacologia , Tumores Neuroendócrinos/tratamento farmacológico , Tumores Neuroendócrinos/metabolismo , Octreotida/farmacocinética , Adulto , Idoso , Antineoplásicos/efeitos adversos , Antineoplásicos/sangue , Preparações de Ação Retardada , Progressão da Doença , Intervalo Livre de Doença , Método Duplo-Cego , Interações Medicamentosas , Determinação de Ponto Final , Everolimo/efeitos adversos , Everolimo/sangue , Feminino , Humanos , Pneumopatias/induzido quimicamente , Pneumopatias/epidemiologia , Masculino , Pessoa de Meia-Idade , Octreotida/efeitos adversos , Octreotida/sangue , Estudos Prospectivos , Risco , Segurança
9.
Acta Oncol ; 55(1): 68-76, 2016.
Artigo em Inglês | MEDLINE | ID: mdl-25813472

RESUMO

BACKGROUND: (177)Lu-octreotate therapy has proven to give favorable results after treatment of patients with neuroendocrine tumors. Much focus has been on the binding and uptake of (177)Lu-octreotate in tumor tissue, but biodistribution properties in normal tissues is still not fully understood, and the effect of receptor saturation may be important. The aim of this study was to investigate the influence of the amount of (177)Lu-octreotate on the biodistribution of (177)Lu-octreotate in normal tissues in mice. MATERIAL AND METHODS: C57BL/6N female mice were intravenously injected with 0.1-150 MBq (177)Lu-octreotate (0.039 µg peptide/MBq). The mice were killed 0.25 h to 14 days after injection by cardiac puncture under anesthesia. Activity concentration was determined in blood, bone marrow, kidneys, liver, lungs, pancreas, and spleen, and mean absorbed doses were calculated. RESULTS: The activity concentration varied with time and amount of injected activity. At 4-8 h after injection, a local maximum in activity concentration was found for liver, lungs, pancreas, and spleen. With the exception for the lower injected activities (0.1-1 MBq), the overall highest uptake was found in the kidneys (%IA/g). Large variations were found and the activity concentration in kidneys was 11-23%IA/g at 4 h, and 0.22-1.9%IA/g at 7 days after injection. Furthermore, a clear reduction in activity concentration with increased injected activity was observed for lungs, pancreas and spleen. CONCLUSION: The activity concentration in all tissues investigated was strongly influenced by the amount of (177)Lu-octreotate injected. Large differences in mean absorbed dose per unit injected activity were found between low (0.1-1 MBq, 0.0039-0.039 µg) and moderate amounts (5-45 MBq, 0.2-1.8 µg). Furthermore, the results clearly showed the need for better ways to estimate absorbed dose to bone marrow other than methods based on a single blood sample analysis. Since the absorbed dose to critical organs will limit the amount of (177)Lu-octreotate administered, these findings must be taken into consideration when optimizing this type of therapy.


Assuntos
Octreotida/análogos & derivados , Animais , Medula Óssea/metabolismo , Feminino , Rim/metabolismo , Fígado/metabolismo , Pulmão/metabolismo , Camundongos , Camundongos Endogâmicos C57BL , Octreotida/administração & dosagem , Octreotida/sangue , Octreotida/farmacocinética , Pâncreas/metabolismo , Baço/metabolismo , Fatores de Tempo , Distribuição Tecidual
10.
Clin Biochem ; 47(1-2): 139-41, 2014 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-23872204

RESUMO

OBJECTIVES: The aim of this study was to develop and validate a fast liquid chromatography-tandem mass spectrometric (LC-MSMS) assay to determine circulating concentrations of octreotide (a somatostatin analog used in acromegaly and neuroendocrine tumors) in patients' plasma samples. DESIGN AND METHODS: 500 µL of heparin-plasma was used to extract the drug on a cation exchanger SPE column, and the eluate was injected into a LC-MSMS system. Reversed phase chromatography was performed on a phenyl grafted column in isocratic mode. Octreotide and internal standard (triptorelin) were identified in positive electrospray ionization mode using ion transitions of m/z 512>120 and 890>249, respectively. RESULTS: The assay was linear in the concentration range of 0.5-25 ng/mL, with intra- and inter-assay imprecisions of <10.6% and <12.2%, respectively. The limits of quantification and detection were 0.5 and 0.25 ng/mL. The recovery and ion suppression effect ranged between 79.7 and 84.5% and between -8.1 and -21.3%, respectively. A subcutaneous injection of 0.1mg octreotide induced a time- and patient-dependent surge of peptide concentrations peaking at 2h. CONCLUSION: This fast, sensitive, and selective method for quantification of plasma octreotide by LC-MSMS might be used to investigate the pharmacokinetic-pharmacodynamic relationship, with potential contribution to treatment optimization and therapeutic drug monitoring application.


Assuntos
Cromatografia Líquida/métodos , Octreotida/sangue , Espectrometria de Massas em Tandem/métodos , Humanos , Limite de Detecção , Padrões de Referência
11.
Drug Test Anal ; 6(5): 415-25, 2014 May.
Artigo em Inglês | MEDLINE | ID: mdl-23918459

RESUMO

Online 2-dimensional chromatographic approaches for eliminating matrix effects and optimizing bioanalysis of peptides using ultra-high performance liquid chromatography-tandem mass spectrometry (UHPLC-MS/MS) were studied. Three therapeutic peptides (octreotide, desmopressin, and vasopressin) were selected as model analytes. Human plasma was precipitated with acetonitrile; peptides were analyzed on C(8), C(18), Phenyl and HILIC ACQUITY UPLC columns. For simpler online clean-up applications, a C(18) pre-column was coupled to the analytical column via a switching valve. For more complex heart-cutting applications, two analytical columns were used with optional online dilution to refocus the analyte peaks prior to the second dimension separation. This allows the use of MS incompatible mobile phases, such as TFA, in the first dimension separation. Online clean-up effectiveness was investigated by monitoring phospholipids. Flushing direction, mobile phase composition, flow rate and transfer window were evaluated. Phospholipids were readily retained on reversed-phase columns, and the peptides were reproducibly transferred, individually or as a group, to the second column using appropriate transfer windows. The best peak shapes were obtained when the second dimension column was more retentive (e.g. C(18) vs. C(8)). However, C(8) to HILIC gave broad unresolved peaks due to mobile phase mismatch. Trapped phospholipids were efficiently removed from either guard columns or first dimensional columns by forward- or back-flushing at high flows; however, back-flushing was more efficient with lower flow rates on larger columns.


Assuntos
Cromatografia Líquida de Alta Pressão/métodos , Peptídeos/sangue , Espectrometria de Massas em Tandem/métodos , Desamino Arginina Vasopressina/sangue , Humanos , Octreotida/sangue , Peptídeos/química , Fosfolipídeos/análise , Vasopressinas/sangue
12.
Eur J Nucl Med Mol Imaging ; 40(12): 1853-60, 2013 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-23864305

RESUMO

PURPOSE: The aim of the study was to investigate the feasibility of shortening the recommended 4-h renoprotective amino acid infusion in patients receiving peptide receptor chemoradionuclide therapy (PRCRT) using radiosensitizing 5-fluorouracil. We evaluated the clearance of radiopeptide from the blood, long-term nephrotoxicity in patients undergoing PRCRT with the conventional 4-h amino acid infusion and renal uptake in patients receiving an abbreviated infusion. METHODS: The whole-blood clearance of (177)Lu-DOTA-octreotate (LuTate) was measured in 13 patients receiving PRCRT. A retrospective analysis of short-term and long-term changes in glomerular filtration rate (GFR) in 96 consecutive patients receiving a 4-h infusion was performed. Renal LuTate retention estimated using quantitative SPECT/CT in 22 cycles delivered with a 2.5-h amino acid infusion was compared with that in 72 cycles with the 4-h infusion. RESULTS: LuTate demonstrated biexponential blood clearance with an initial clearance half-time of 21 min. Approximately 88 % of blood activity was cleared within 2 h. With the 4-h protocol, there was no significant change in GFR (1.2 ml/min mean increase from baseline; 95 % CI -6.9 to 4.4 ml/min) and no grade 3 or 4 nephrotoxicity at the end of induction PRCRT. The long-term decline in GFR after a median follow up of 22 months was 2.2 ml/min per year. There was no significant difference in the renal LuTate retention measured in patients receiving a 2.5-h amino acid infusion compared to those who had a 4-h infusion. CONCLUSION: The greatest renal exposure to circulating radiopeptide occurs in the first 1 - 2 h after injection. This, combined with the safety of LuTate PRCRT, allows consideration of an abbreviated amino acid infusion, increasing patient convenience and reducing human resource allocation.


Assuntos
Aminoácidos/administração & dosagem , Aminoácidos/farmacologia , Citoproteção/efeitos dos fármacos , Rim/efeitos dos fármacos , Octreotida/análogos & derivados , Compostos Organometálicos/efeitos adversos , Compostos Organometálicos/farmacocinética , Adulto , Idoso , Transporte Biológico/efeitos dos fármacos , Quimiorradioterapia/efeitos adversos , Estudos de Coortes , Estudos de Viabilidade , Feminino , Humanos , Rim/efeitos da radiação , Masculino , Pessoa de Meia-Idade , Octreotida/efeitos adversos , Octreotida/sangue , Octreotida/farmacocinética , Octreotida/uso terapêutico , Compostos Organometálicos/sangue , Compostos Organometálicos/uso terapêutico , Receptores de Peptídeos/metabolismo , Estudos Retrospectivos , Fatores de Tempo , Adulto Jovem
13.
Endocr J ; 60(10): 1165-9, 2013.
Artigo em Inglês | MEDLINE | ID: mdl-23856885

RESUMO

Acromegaly is frequently accompanied by left ventricular hypertrophy (LVH) which causes ventricular dysfunction. Ventricular arrhythmia is one of the important complications in acromegalic patients. Hypertrophic cardiomyopathy (HCM) is characterized by LVH with a nondilated chamber. About 10 % of HCM evolve into dilated phase of HCM, which is associated with an increased incidence of ventricular tachycardia (VT). However there is no report about a combination of dilated phase of HCM and VT in acromegalic patients. Octreotide is a somatostatin analog that has been used for medical therapy for acromegaly. We herein report that the first case of the change of serum octreotide concentration affected the control of VT, which was induced by dilated phase of HCM. A 56-year-old Japanese man was referred to our hospital for treatment of acromegaly. The patient was diagnosed the dilated phase of HCM with sustained VT. The frequency and severity of VT were gradually ameliorated by subcutaneous octreotide injection. However VT was deteriorated when its injection was changed to octreotide long-acting release (LAR) injection. The temporary drop in serum octreotide concentration was known at the transition from subcutaneous injection to LAR injection. This clinical course gives us the important information that subcutaneous octreotide injection for two weeks should be necessary to keep serum octreotide concentration when switing to octreotide LAR administration in acromegalic patients with severe arrhythmia.


Assuntos
Acromegalia/complicações , Cardiomiopatia Hipertrófica/complicações , Hipertrofia Ventricular Esquerda/etiologia , Octreotida/administração & dosagem , Octreotida/sangue , Taquicardia Ventricular/tratamento farmacológico , Acromegalia/sangue , Preparações de Ação Retardada/efeitos adversos , Humanos , Masculino , Taquicardia Ventricular/etiologia
14.
Endocr J ; 60(8): 951-7, 2013.
Artigo em Inglês | MEDLINE | ID: mdl-23665775

RESUMO

A 73-year-old woman with malignant insulinoma was treated with 100 µg/day octreotide for unresected insulinoma and liver metastases. The daily administration of the drug induced hyperglycemia after dinner in addition to existing fasting hypoglycemia possibly because this drug suppressed both insulin and glucagon secretion and its blood concentration was unstable. After replacing a daily injection of octreotide with a monthly injection of octreotide long-acting repeatable (LAR), blood glucose levels stabilized within the normal range. The findings of the present study showed that octreotide LAR could be useful for the long-term treatment of unresectable insulinomas.


Assuntos
Glicemia/metabolismo , Insulinoma/tratamento farmacológico , Octreotida/administração & dosagem , Neoplasias Pancreáticas/tratamento farmacológico , Idoso , Glicemia/efeitos dos fármacos , Preparações de Ação Retardada/administração & dosagem , Feminino , Humanos , Hipoglicemia/induzido quimicamente , Insulinoma/patologia , Neoplasias Hepáticas/tratamento farmacológico , Neoplasias Hepáticas/secundário , Octreotida/efeitos adversos , Octreotida/sangue , Neoplasias Pancreáticas/patologia
15.
Growth Factors ; 31(2): 66-73, 2013 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-23452315

RESUMO

We aimed to investigate the involvement of growth hormone in dawn phenomenon and insulin sensitivity in patients with type 2 diabetes mellitus (T2DM). On six occasions separated by intervals of at least 3 days, subjects received early evening (16:00 hours) or late night (23:00 hours) pretreatment with subcutaneous injection of normal saline, human growth hormone, or octreotide. Modified euglycemic insulin clamp test was done 16 hours later and variable glucose infusion (M values) was determined. Plasma glucose, serum insulin, insulin-like growth factor-1, non-esterified fatty acids, and metabolic clearance rate of insulin (MCRI) were measured. Early evening application of growth hormone decreased MCRI 16 hours later, suggesting reduction in insulin sensitivity. Exogenous growth hormone injection reduced insulin sensitivity in T2DM patients. Results provide direct evidence for the role of growth hormone in regulating the insulin sensitivity in insulin-resistant patients.


Assuntos
Diabetes Mellitus Tipo 2/sangue , Cronofarmacoterapia , Hormônio do Crescimento Humano/sangue , Hormônio do Crescimento Humano/farmacologia , Resistência à Insulina , Adulto , Glicemia/análise , Diabetes Mellitus Tipo 2/tratamento farmacológico , Feminino , Técnica Clamp de Glucose , Hormônio do Crescimento Humano/administração & dosagem , Humanos , Masculino , Octreotida/administração & dosagem , Octreotida/sangue , Octreotida/farmacologia
16.
Eur J Pharm Sci ; 48(1-2): 87-96, 2013 Jan 23.
Artigo em Inglês | MEDLINE | ID: mdl-23131800

RESUMO

The objective of this study was to develop a controlled delivery system for PEGylated octreotide using a Poloxamer based in situ gel forming polymer. PEGylated octreotide kept its full biological activity and higher serum half-life compared to the original octreotide. The designed drug delivery system contained low concentration of Poloxamer 407 (P407) (<0.16%) with polyvinyl alcohol (PVA) as a polymeric additive. Rheological measurements of gel vehicle formulations indicated that the in situ gel forming system with optimum sol-gel transition temperature of 28.7°C could be formed using a combination of P407 and PVA at ratio of 15-10% (w/v). The effect of formulation additives such as buffering agents on rheological behavior demonstrated that sodium bicarbonate and lactic acid have opposite effect on sol-gel transition temperature of the system. Using buffering agents, it was possible to shift the sol-gel transition to lower or higher temperatures. The in vitro release profiles of octreotide and PEGylated octreotide from the selected P407/PVA formulations were measured using a membrane-less device. PEGylated octreotide showed slower release rate from the gel system with different release kinetic compared to octreotide. In animal studies, a sustained release rate was achieved with both PEGylated and non-PEGylated octreotide, but longer delivery was observed for PEGylated octreotide. Tissue histopathological studies confirmed the biocompatibility of the delivery system for PEGylated octreotide, supporting the suitability of P407/PVA mixture as an injectable drug delivery system. The total effects of increasing PEGylated peptide half-life and prolonged release from thermoresponsive gel system offer the potential for sustained delivery of PEGylated octreotide.


Assuntos
Sistemas de Liberação de Medicamentos , Octreotida/administração & dosagem , Polietilenoglicóis/administração & dosagem , Animais , Contagem de Células , Preparações de Ação Retardada/administração & dosagem , Preparações de Ação Retardada/química , Preparações de Ação Retardada/farmacocinética , Eosinófilos/efeitos dos fármacos , Géis , Injeções Subcutâneas , Macrófagos/efeitos dos fármacos , Masculino , Neutrófilos/efeitos dos fármacos , Octreotida/sangue , Octreotida/química , Octreotida/farmacocinética , Poloxâmero/química , Polietilenoglicóis/química , Polietilenoglicóis/farmacocinética , Álcool de Polivinil/química , Ratos , Ratos Sprague-Dawley , Reologia
18.
Eur J Endocrinol ; 166(2): 333-9, 2012 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-22048969

RESUMO

CONTEXT: Congenital hyperinsulinism (HI) is a common cause of hypoglycemia in infancy. The medical treatment of diazoxide-unresponsive HI is based on a somatostatin analogue. OBJECTIVE: This study aims at replacing three daily s.c. octreotide (Sandostatin, Novartis) injections by a single and monthly i.m. injection of long-acting release (LAR) octreotide (Sandostatin LP, Novartis) in HI patients. SUBJECTS AND METHOD: LAR octreotide was injected every 4 weeks during 6 months and s.c. octreotide injections were stopped after the third injection of LAR octreotide. After this 6-month study, LAR octreotide was continued, with an average follow-up of 17 months. Ten HI pediatric patients unresponsive to diazoxide and currently treated with s.c. octreotide were included in the trial. Glycemias and other parameters (HbA1c, IGF1, height, weight, quality of life (QoL), and satisfaction) were monitored at each monthly visit. RESULTS: For all ten patients, glycemias were maintained in the usual range, HbAlc (mean 5.5%; 95% CI: 4.6-6.2) and IGF1 (mean 89.7 ng/ml; 95% CI: 26-153) were unchanged. Patients gained height significantly (mean 2.7 cm; 95% CI: 1.9-3.4) and no side effect was noted during the study and the later follow-up. Plasma octreotide levels were stable under LAR octreotide. Parents' questionnaires of general satisfaction were highly positive whereas children's QoL evaluation remained unchanged. CONCLUSION: In these diazoxide-unresponsive HI patients, LAR octreotide was efficient, well tolerated and contributed to a clear simplification of the medical care.


Assuntos
Hiperinsulinismo Congênito/tratamento farmacológico , Octreotida/administração & dosagem , Transportadores de Cassetes de Ligação de ATP/genética , Criança , Pré-Escolar , Hiperinsulinismo Congênito/sangue , Hiperinsulinismo Congênito/genética , Hiperinsulinismo Congênito/metabolismo , Preparações de Ação Retardada , Feminino , Seguimentos , Fármacos Gastrointestinais/administração & dosagem , Fármacos Gastrointestinais/efeitos adversos , Humanos , Lactente , Injeções Intramusculares/efeitos adversos , Injeções Subcutâneas/efeitos adversos , Masculino , Octreotida/efeitos adversos , Octreotida/sangue , Octreotida/farmacocinética , Canais de Potássio Corretores do Fluxo de Internalização/genética , Receptores de Droga/genética , Receptores de Sulfonilureias , Resultado do Tratamento
19.
AAPS PharmSciTech ; 12(4): 1293-301, 2011 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-21948321

RESUMO

The study reports on the drug release behavior of a potent synthetic somatostatin analogue, octreotide acetate, from biocompatible and biodegradable microspheres composed of poly-lactic-co-glycolic acid (PLGA) following a single intramuscular depot injection. The serum octreotide levels of three Oakwood Laboratories formulations and one Sandostatin LAR(®) formulation were compared. Three formulations of octreotide acetate-loaded PLGA microspheres were prepared by a solvent extraction and evaporation procedure using PLGA polymers with different molecular weights. The in vivo drug release study was conducted in male Sprague-Dawley rats. Blood samples were taken at predetermined time points for up to 70 days. Drug serum concentrations were quantified using a radioimmunoassay procedure consisting of radiolabeled octreotide. The three octreotide PLGA microsphere formulations and Sandostatin LAR(®) all showed a two-phase drug release profile (i.e., bimodal). The peak serum drug concentration of octreotide was reached in 30 min for all formulations followed by a decline after 6 h. Following this initial burst and decline, a second-release phase occurred after 3 days. This second-release phase exhibited sustained-release behavior, as the drug serum levels were discernible between days 7 and 42. Using pharmacokinetic computer simulations, it was estimated that the steady-state octreotide serum drug levels would be predicted to fall in the range of 40-130 pg/10 µL and 20-100 pg/10 µL following repeat dosing of the Oakwood formulations and Sandostatin LAR(®) every 28 days and every 42 days at a dose of 3 mg/rat, respectively.


Assuntos
Portadores de Fármacos , Ácido Láctico/química , Octreotida/farmacocinética , Ácido Poliglicólico/química , Animais , Química Farmacêutica , Simulação por Computador , Composição de Medicamentos , Implantes de Medicamento , Injeções Intramusculares , Masculino , Microesferas , Modelos Biológicos , Octreotida/administração & dosagem , Octreotida/sangue , Octreotida/química , Copolímero de Ácido Poliláctico e Ácido Poliglicólico , Radioimunoensaio , Ratos , Ratos Sprague-Dawley , Solubilidade , Tecnologia Farmacêutica/métodos
20.
Nucl Med Biol ; 38(6): 917-24, 2011 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-21843788

RESUMO

INTRODUCTION: The low-energy ß(-) emitter (161)Tb is very similar to (177)Lu with respect to half-life, beta energy and chemical properties. However, (161)Tb also emits a significant amount of conversion and Auger electrons. Greater therapeutic effect can therefore be expected in comparison to (177)Lu. It also emits low-energy photons that are useful for gamma camera imaging. METHODS: The (160)Gd(n,γ)(161)Gd→(161)Tb production route was used to produce (161)Tb by neutron irradiation of massive (160)Gd targets (up to 40 mg) in nuclear reactors. A semiautomated procedure based on cation exchange chromatography was developed and applied to isolate no carrier added (n.c.a.) (161)Tb from the bulk of the (160)Gd target and from its stable decay product (161)Dy. (161)Tb was used for radiolabeling DOTA-Tyr3-octreotate; the radiolabeling profile was compared to the commercially available n.c.a. (177)Lu. A (161)Tb Derenzo phantom was imaged using a small-animal single-photon emission computed tomography camera. RESULTS: Up to 15 GBq of (161)Tb was produced by long-term irradiation of Gd targets. Using a cation exchange resin, we obtained 80%-90% of the available (161)Tb with high specific activity, radionuclide and chemical purity and in quantities sufficient for therapeutic applications. The (161)Tb obtained was of the quality required to prepare (161)Tb-DOTA-Tyr3-octreotate. CONCLUSIONS: We were able to produce (161)Tb in n.c.a. form by irradiating highly enriched (160)Gd targets; it can be obtained in the quantity and quality required for the preparation of (161)Tb-labeled therapeutic agents.


Assuntos
Partículas beta/uso terapêutico , Elétrons , Lutécio/química , Radioquímica/métodos , Radioisótopos/química , Radioterapia/métodos , Térbio/química , Humanos , Lutécio/isolamento & purificação , Lutécio/uso terapêutico , Reatores Nucleares , Octreotida/análogos & derivados , Octreotida/sangue , Compostos Organometálicos/sangue , Radioisótopos/isolamento & purificação , Radioisótopos/uso terapêutico , Térbio/isolamento & purificação , Térbio/uso terapêutico
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...